Krystal Biotech, Inc. 2,666,667 Shares Common Stock ($0.00001 par value) Underwriting AgreementKrystal Biotech, Inc. • December 3rd, 2021 • Biological products, (no disgnostic substances) • New York
Krystal Biotech, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Goldman Sachs & Co. LLC (“Goldman Sachs”), BofA Securities, Inc., (“BofA”),Cowen and Company, LLC (“Cowen”) and William Blair & Company, L.L.C. (“William Blair”), are acting as representatives (the “Representatives”), 2,666,667 shares of common stock, $0.00001 par value per share (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer and the entities named in Schedule IV hereto (each a “Selling Stockholder” and together, the “Selling Stockholders”) also propose to grant to the Underwriters an option to purchase up to 200,000 additional shares of Common Stock set forth in Schedule II (the “Issuer Option Securities”) and up to 200,000
